190 related articles for article (PubMed ID: 23962557)
1. Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells.
Horwacik I; Durbas M; Boratyn E; Węgrzyn P; Rokita H
Cancer Lett; 2013 Dec; 341(2):248-64. PubMed ID: 23962557
[TBL] [Abstract][Full Text] [Related]
2. GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells.
Durbas M; Pabisz P; Wawak K; Wiśniewska A; Boratyn E; Nowak I; Horwacik I; Woźnicka O; Rokita H
Apoptosis; 2018 Oct; 23(9-10):492-511. PubMed ID: 30027525
[TBL] [Abstract][Full Text] [Related]
3. Apoptosis is responsible for the cytotoxic effects of anti-GD2 ganglioside antibodies and aurora A kinase inhibitors on human neuroblastoma cells.
Durbas M; Rokita H; Horwacik I; Wiśniewska A; Nowak I
Acta Biochim Pol; 2022 Jul; 69(3):485-494. PubMed ID: 35810485
[TBL] [Abstract][Full Text] [Related]
4. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
[TBL] [Abstract][Full Text] [Related]
5. Analysis of genes involved in response to doxorubicin and a GD2 ganglioside-specific 14G2a monoclonal antibody in IMR-32 human neuroblastoma cells.
Horwacik I; Durbas M; Boratyn E; Sawicka A; Węgrzyn P; Krzanik S; Górka A; Drożniak J; Augustyniak E; Kowalczyk A; Rokita H
Acta Biochim Pol; 2015; 62(3):423-33. PubMed ID: 26284262
[TBL] [Abstract][Full Text] [Related]
6. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.
Horwacik I; Rokita H
Int J Oncol; 2017 May; 50(5):1899-1914. PubMed ID: 28393238
[TBL] [Abstract][Full Text] [Related]
7. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of the PHLDA1 gene in IMR-32 neuroblastoma cells increases levels of Aurora A, TRKB and affects proteins involved in apoptosis and autophagy pathways.
Durbas M; Horwacik I; Boratyn E; Rokita H
Int J Oncol; 2016 Aug; 49(2):823-37. PubMed ID: 27278006
[TBL] [Abstract][Full Text] [Related]
9. Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.
Liu B; Wu Y; Zhou Y; Peng D
PLoS One; 2014; 9(4):e93576. PubMed ID: 24727660
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinases as targets in drug-resistant neuroblastoma cells.
Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
[TBL] [Abstract][Full Text] [Related]
11. Selection of novel peptide mimics of the GD2 ganglioside from a constrained phage-displayed peptide library.
Horwacik I; Czaplicki D; Talarek K; Kowalczyk A; Bolesta E; Kozbor D; Rokita H
Int J Mol Med; 2007 May; 19(5):829-39. PubMed ID: 17390090
[TBL] [Abstract][Full Text] [Related]
12. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
13. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
14. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
15. Analysis and optimization of interactions between peptides mimicking the GD2 ganglioside and the monoclonal antibody 14G2a.
Horwacik I; Kurciński M; Bzowska M; Kowalczyk AK; Czaplicki D; Koliński A; Rokita H
Int J Mol Med; 2011 Jul; 28(1):47-57. PubMed ID: 21455557
[TBL] [Abstract][Full Text] [Related]
16. [Caspases participarion in the cell death induced by GD2-specific monoclonal antibody].
Vishniakova PA; Doronin II; Holodenko IV; Riazantsev DIu; Molotkovskaia IM; Holodenko RV
Bioorg Khim; 2014; 40(3):305-14. PubMed ID: 25898737
[TBL] [Abstract][Full Text] [Related]
17. Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.
Ramaiah MJ; Pushpavalli SN; Lavanya A; Bhadra K; Haritha V; Patel N; Tamboli JR; Kamal A; Bhadra U; Pal-Bhadra M
Bioorg Med Chem Lett; 2013 Oct; 23(20):5699-706. PubMed ID: 23992861
[TBL] [Abstract][Full Text] [Related]
18. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
[TBL] [Abstract][Full Text] [Related]
19. Anti-ganglioside GD2 monoclonal antibody synergizes with cisplatin to induce endoplasmic reticulum-associated apoptosis in osteosarcoma cells.
Zhu W; Mao X; Wang W; Chen Y; Li D; Li H; Dou P
Pharmazie; 2018 Feb; 73(2):80-86. PubMed ID: 29442009
[TBL] [Abstract][Full Text] [Related]
20. GSK3 inhibitors regulate MYCN mRNA levels and reduce neuroblastoma cell viability through multiple mechanisms, including p53 and Wnt signaling.
Duffy DJ; Krstic A; Schwarzl T; Higgins DG; Kolch W
Mol Cancer Ther; 2014 Feb; 13(2):454-67. PubMed ID: 24282277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
